Glucocorticoid Use Ups Diabetes Risk in Rheumatoid Arthritis

This article originally appeared here.
Share this content:
Glucocorticoid Use Ups Diabetes Risk in Rheumatoid Arthritis
Glucocorticoid Use Ups Diabetes Risk in Rheumatoid Arthritis

TUESDAY, May 31, 2016 (HealthDay News) -- For patients with rheumatoid arthritis (RA), glucocorticoid treatment is associated with increased risk of diabetes mellitus (DM), according to a study published in the May issue of Arthritis & Rheumatology.

Mohammad Movahedi, M.D., Ph.D., from the University of Manchester in the United Kingdom, and colleagues conducted a cohort study using two databases: the Clinical Practice Research Datalink (CPRD), with 21,962 RA patients, and the U.S. National Data Bank for Rheumatic Diseases (NBD), with 12,657 RA patients. Data were extracted on the dosage and timing of glucocorticoid use.

The researchers found that, compared with nonusers, current glucocorticoid users had hazard ratios of 1.30 and 1.61 for DM in the CPRD and NDB, respectively. Increases in risk were confirmed with glucocorticoid dosage and duration in a range of conventional statistical models. In a novel weighted cumulative dose model, recent glucocorticoid use contributed most to the current risk of DM; current risk was not influenced by doses taken more than six months previously. In the CPRD, hazard ratios of 1.20, 1.43, and 1.48 were seen for 5 mg of prednisolone equivalent dose for the last one, three, and six months, respectively, compared with nonusers.

"Glucocorticoid use is a clinically important and quantifiable risk factor for DM," the authors write. "Risk is influenced by the dosage and treatment duration, although only for glucocorticoid use within the last six months."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »